Bristol-Myers Squibb Appoints Mike Burgess M.D., Ph.D. Senior Vice President, Discovery Medicine and Clinical Pharmacology

Thu Jan 17, 2013 2:00pm EST

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130117:nBw176247a

NEW YORK--(Business Wire)--
Bristol-Myers Squibb Company (NYSE: BMY) today announced that Mike Burgess M.D.,
Ph.D. has joined the Company as senior vice president, Discovery Medicine and
Clinical Pharmacology. He will report to Francis Cuss, MB BChir, FRCP, senior
vice president, Research, R&D, Bristol-Myers Squibb, and will be a member of the
Research Senior Leadership Team. 

"As a physician scientist with a Ph.D. in molecular biology, clinical experience
in pediatrics and pediatric oncology, and extensive pharmaceutical industry and
leadership experience, I believe Mike will be an important addition to our
research and development organization," said Dr. Cuss. "Mike`s broad clinical
expertise, cross-therapeutic global team leadership and proven operational
excellence will enable Bristol-Myers Squibb to continue to execute its strategy
of ensuring sustainable delivery of an innovative pipeline of new medicines for
patients." 

Before joining Bristol-Myers Squibb, Dr. Burgess was interim head of Hoffman
La-Roche`s Pharma Research and Early Development organization. Prior to that he
led the Hoffman La-Roche Oncology Discovery and Translational Area, one of five
disease-focused organizations, and at the same time served as head of Global
Large Molecule Research. Before joining Hoffman La-Roche, Dr. Burgess was at Eli
Lilly and Company as a Medical Fellow. He received his medical training and
Ph.D. from the University of Bristol, U.K., and is a member of the Royal College
of Physicians and of the Royal College of Pediatrics and Child Health. 

"I am excited by the opportunity to join Bristol-Myers Squibb and its Research
Leadership Team," said Dr. Burgess. "Bristol-Myers Squibb is well known and
respected for its innovative pipeline and approach to discovering and developing
new medicines. I am looking forward to joining this committed team and
continuing to drive research that delivers a differentiated pipeline of
potential new medicines." 

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to
discover, develop and deliver innovative medicines that help patients prevail
over serious diseases. For more information, please visit www.bms.com or follow
us on Twitter at http://twitter.com/bmsnews.

Bristol-Myers Squibb
Media:
Jennifer Fron Mauer, 609-252-6579; jennifer.mauer@bms.com
or
Investors: John Elicker, 609-252-4611; john.elicker@bms.com



Copyright Business Wire 2013